Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampin combination therapy versus monotherapy for early staphylococcal prosthetic joint infection after hip or knee arthroplasty
2005-005494-29Phase 4Completed
- Sponsor
- Ullevål University Hospital
- Start
- Jan 2006
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rifampicin, cloxacillin, vancomycin and probenecid in periprosthetic joint infection (PJI) and Staphylococcosis (2 arms), sponsored by Ullevål University Hospital. Started Jan 2006; status: completed.
02
Drugs
rifampicincloxacillinvancomycinprobenecid
03
Conditions
periprosthetic joint infection (PJI)Staphylococcosis
Beyond the preview
Go deeper on 2005-005494-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005494-29.